Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JAC/DKW276PMID 27494912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

  2015cited by this paper
• Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus

  2015cited by this paper
• Combination Antifungal Therapy for Invasive Aspergillosis

  2015cited by this paper
• Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies

  2015cited by this paper
• Optimization of Polyene-Azole Combination Therapy against Aspergillosis Using an In Vitro Pharmacokinetic-Pharmacodynamic Model

  2015cited by this paper
• Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach

  2015cited by this paper
• Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.

  2014cited by this paper
• Population Pharmacokinetic Analysis of Voriconazole and Anidulafungin in Adult Patients with Invasive Aspergillosis

  2014cited by this paper
• Susceptibility Breakpoints for Amphotericin B and Aspergillus Species in an In Vitro Pharmacokinetic-Pharmacodynamic Model Simulating Free-Drug Concentrations in Human Serum

  2014cited by this paper
• Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.

  2013cited by this paper
• Pharmacokinetics of Anidulafungin in Critically Ill Patients with Candidemia/Invasive Candidiasis

  2013cited by this paper
• Assessment of Efficacy of Antifungals against Aspergillus fumigatus: Value of Real-Time Bioluminescence Imaging

  2013cited by this paper
• Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal.

  2013cited by this paper
• In Vitro Combination of Anidulafungin and Voriconazole against Intrinsically Azole-Susceptible and -Resistant Aspergillus spp

  2012cited by this paper
• Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant Aspergillus fumigatus in an In Vitro Model of Invasive Pulmonary Aspergillosis

  2012cited by this paper
• In Vitro Pharmacokinetic/Pharmacodynamic Modeling of Voriconazole Activity against Aspergillus Species in a New In Vitro Dynamic Model

  2012cited by this paper
• In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.

  2012cited by this paper
• In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant Aspergillus fumigatus

  2012cited by this paper
• Population Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Adult Patients with Fungal Infections

  2012cited by this paper
• Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

  2011cited by this paper
• Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

  2011cited by this paper
• Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a New In Vitro Pharmacokinetic/Pharmacodynamic Model

  2011cited by this paper
• Current Role of Echinocandins in the Management of Invasive Aspergillosis

  2011cited by this paper
• Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009

  2011cited by this paper
• Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

  2010cited by this paper
• Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

  2010cited by this paper
• Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin

  2009cited by this paper
• Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

  2009cited by this paper
• In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method

  2009cited by this paper
• Susceptibility Testing of Anidulafungin and Voriconazole Alone and in Combination against Conidia and Hyphae of Aspergillus spp. under Hypoxic Conditions

  2008cited by this paper
• Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

  2008cited by this paper
• Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins

  2008cited by this paper
• In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model

  2007cited by this paper
• Comparative In Vitro Pharmacodynamics of Caspofungin, Micafungin, and Anidulafungin against Germinated and Nongerminated Aspergillus Conidia

  2007cited by this paper
• Concentration-Dependent Synergy and Antagonism within a Triple Antifungal Drug Combination against Aspergillus Species: Analysis by a New Response Surface Model

  2007cited by this paper
• The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.

  2006cited by this paper
• Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation.

  2006cited by this paper
• A consensus on fungal polymerase chain reaction diagnosis?: a United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections.

  2006cited by this paper
• Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.

  2005cited by this paper
• Combination Antifungal Therapy for Invasive Aspergillosis

  2005cited by this paper
• Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

  2004cited by this paper
• The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

  2003cited by this paper
• In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance

  2002cited by this paper
• Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens

  2002cited by this paper
• Synergistic action of nikkomycin X/Z with azole antifungals on Candida albicans.

  1991cited by this paper
• Nature and development of phenotypic resistance to amphotericin B in Candida albicans.

  1986cited by this paper

• Invasive Aspergillosis in the Intensive Care Unit

  2025cites this paper
• Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics

  2025cites this paper
• Azole-Resistant Aspergillus fumigatus: Epidemiology, Diagnosis, and Treatment Considerations

  2025cites this paper
• In Vitro–In Vivo Correlation of Posaconazole–Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations Are Associated with In Vivo Free Drug Levels

  2023cites this paper
• Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children

  2022cites this paper
• Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?

  2021cites this paper
• Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?

  2020cites this paper
• Combination Therapy for Invasive Fungal Infections

  2020cites this paper
• The first rare and fatal case of invasive aspergillosis of spinal cord due to Aspergillus nidulans in an Iranian child with chronic granulomatosis disease: review of literature

  2020cites this paper
• In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates

  2020cites this paper
• Prevention of drug-related complications in cystic fibrosis.

  2019cites this paper
• Clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI

  2019cites this paper
• Aspergillus fumigatus and Aspergillosis in 2019

  2019cites this paper
• Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies.

  2019cites this paper
• Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside

  2019cites this paper
• Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis

  2019cites this paper
• Evaluation of the efficacy of a posaconazole and anidulafungin combination in a murine model of pulmonary aspergillosis due to infection with Aspergillus fumigatus.

  2018cites this paper
• How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients

  2018cites this paper
• A New Marker of Echinocandin Activity in an In Vitro Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection

  2018cites this paper
• Prévention, contrôle et maîtrise du risque d’aspergillose invasive au Groupement Hospitalier Edouard Herriot lors de travaux : apport de la surveillance et de l’alerte environnementale et épidémiologique

  2017cites this paper
• Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia

  2017cites this paper
• In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp

  2017cites this paper
• Comparison Between Etest and Broth Microdilution Methods for Testing Itraconazole-Resistant Aspergillus fumigatus Susceptibility to Antifungal Combinations

  2017cites this paper